Although Esan et al. suggest that brain-specific angiogenesis inhibitor-1 (BAI1) could benefit insulin resistance in the liver, the use of this drug is still very limited for people with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) [35]. Here, ADGRB1 is linked to metabolic dysfunction-associated steatotic liver disease.